DNA methylation of the CDH13 tumor suppressor gene is a promising biomarker for various cancers.
This article provides a detailed examination of circulating tumor DNA (ctDNA) extraction techniques from plasma, a critical pre-analytical step in liquid biopsy.
This article provides a comprehensive overview of digital PCR (dPCR) methodologies for sensitive and specific detection of KRAS mutations, crucial biomarkers in colorectal, pancreatic, and other cancers.
This article provides a comprehensive guide to the circulating tumor DNA (ctDNA) analysis workflow, tailored for researchers, scientists, and drug development professionals.
The analysis of circulating tumor DNA (ctDNA) is revolutionizing cancer diagnostics and monitoring, but its accuracy is critically challenged by the presence of clonal hematopoiesis (CH).
Digital PCR (dPCR) represents a transformative advancement in nucleic acid quantification, enabling the absolute quantification of rare genetic mutations with unparalleled sensitivity.
Circulating tumor DNA (ctDNA) analysis has emerged as a transformative tool in precision oncology, enabling non-invasive cancer detection, treatment monitoring, and minimal residual disease assessment.
This article explores the pivotal role of circulating tumor DNA (ctDNA) in advancing precision oncology.
This comprehensive review examines the half-life and clearance dynamics of circulating tumor DNA (ctDNA) and their critical implications for cancer research and drug development.
This article provides a comprehensive analysis of how digital PCR (dPCR) is revolutionizing circulating tumor DNA (ctDNA) research by overcoming critical limitations of quantitative real-time PCR (qPCR).